{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:01:36Z","timestamp":1786982496308,"version":"build-2736575974"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"DOI":"10.1007\/s12664-024-01717-9","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T04:20:16Z","timestamp":1737001216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection"],"prefix":"10.1007","author":[{"given":"Parul","family":"Berry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7619-8338","authenticated-orcid":false,"given":"Sahil","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"1717_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3201\/eid2905.221294","volume":"29","author":"CM Okafor","year":"2023","unstructured":"Okafor CM, Clogher P, Olson D, Niccolai L, Hadler J. Trends in and risk factors for recurrent Clostridioides difficile infection, New Haven County, Connecticut, USA, 2015\u20132020. Emerg Infect Dis. 2023;29:877\u201387. https:\/\/doi.org\/10.3201\/eid2905.221294.","journal-title":"Emerg Infect Dis."},{"key":"1717_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.anaerobe.2018.12.002","volume":"55","author":"L Su\u00e1rez-Bode","year":"2019","unstructured":"Su\u00e1rez-Bode L, Barr\u00f3n R, P\u00e9rez JL, Mena A. Increasing prevalence of the epidemic ribotype 106 in healthcare facility-associated and community-associated Clostridioides difficile infection. Anaerobe. 2019;55:124\u20139. https:\/\/doi.org\/10.1016\/j.anaerobe.2018.12.002.","journal-title":"Anaerobe."},{"key":"1717_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-3-031-42108-2_9","volume":"1435","author":"P Spigaglia","year":"2024","unstructured":"Spigaglia P, Mastrantonio P, Barbanti F. Antibiotic resistances of Clostridioides difficile. Adv Exp Med Biol. 2024;1435:169\u201398. https:\/\/doi.org\/10.1007\/978-3-031-42108-2_9.","journal-title":"Adv Exp Med Biol."},{"issue":"6","key":"1717_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40259-023-00617-2","volume":"37","author":"P Berry","year":"2023","unstructured":"Berry P, Khanna S. Recurrent Clostridioides difficile infection: current clinical management and microbiome-based therapies. BioDrugs. 2023;37:757\u201373. https:\/\/doi.org\/10.1007\/s40259-023-00617-2.","journal-title":"BioDrugs."},{"issue":"1","key":"1717_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12879-023-08096-0","volume":"23","author":"P Feuerstadt","year":"2023","unstructured":"Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023;23:132. https:\/\/doi.org\/10.1186\/s12879-023-08096-0.","journal-title":"BMC Infect Dis."},{"key":"1717_CR6","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.tim.2018.09.004","volume":"26","author":"BK Sandhu","year":"2018","unstructured":"Sandhu BK, McBride SM. Clostridioides difficile. Trends Microbiol. 2018;26:1049\u201350. https:\/\/doi.org\/10.1016\/j.tim.2018.09.004.","journal-title":"Trends Microbiol."},{"issue":"6","key":"1717_CR7","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","volume":"116","author":"CR Kelly","year":"2021","unstructured":"Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021;116(6):1124\u201347. https:\/\/doi.org\/10.14309\/ajg.0000000000001278.","journal-title":"Am J Gastroenterol."},{"key":"1717_CR8","doi-asserted-by":"publisher","first-page":"102517","DOI":"10.1016\/j.anaerobe.2022.102517","volume":"74","author":"TM Monaghan","year":"2022","unstructured":"Monaghan TM, Biswas R, Satav A, Ambalkar S, Kashyap RS. Clostridioides difficile epidemiology in India. Anaerobe. 2022;74:102517. https:\/\/doi.org\/10.1016\/j.anaerobe.2022.102517.","journal-title":"Anaerobe."},{"key":"1717_CR9","doi-asserted-by":"crossref","unstructured":"Monaghan T, Biswas R, Satav A, Ambalkar S, Wilcox M, Kashyap RS. PTH-90 prevalence of Clostridioides difficile infection in Central India: a prospective observational cohort study. BMJ Publishing Group; 2021.","DOI":"10.1136\/gutjnl-2021-BSG.293"},{"key":"1717_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae429","author":"AF Alshannaq","year":"2024","unstructured":"Alshannaq AF, Kates AE, Keating JA, McKinley LL, Dixon JW, Safdar N. Diverse sources and latent reservoirs of community-associated Clostridioides difficile infection. Clin Infect Dis. 2024:ciae429. https:\/\/doi.org\/10.1093\/cid\/ciae429.","journal-title":"Clin Infect Dis."},{"issue":"4","key":"1717_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1017\/ice.2023.18","volume":"44","author":"LK Kociolek","year":"2023","unstructured":"Kociolek LK, Gerding DN, Carrico R, et al. Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44:527\u201349. https:\/\/doi.org\/10.1017\/ice.2023.18.","journal-title":"Infect Control Hosp Epidemiol."},{"issue":"6","key":"1717_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3390\/toxins16060241","volume":"16","author":"MZ Alam","year":"2024","unstructured":"Alam MZ, Madan R. Clostridioides difficile toxins: host cell interactions and their role in disease pathogenesis. Toxins (Basel). 2024;16:241. https:\/\/doi.org\/10.3390\/toxins16060241.","journal-title":"Toxins (Basel)."},{"issue":"6","key":"1717_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/femsre\/fux048","volume":"41","author":"R Chandrasekaran","year":"2017","unstructured":"Chandrasekaran R, Lacy DB. The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev. 2017;41:723\u201350. https:\/\/doi.org\/10.1093\/femsre\/fux048.","journal-title":"FEMS Microbiol Rev."},{"issue":"6","key":"1717_CR14","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1073\/pnas.1311589111","volume":"111","author":"C Schwan","year":"2014","unstructured":"Schwan C, Kruppke AS, N\u00f6lke T, et al. Clostridium difficile toxin CDT hijacks microtubule organization and reroutes vesicle traffic to increase pathogen adherence. Proc Natl Acad Sci U S A. 2014;111:2313\u20138. https:\/\/doi.org\/10.1073\/pnas.1311589111.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"1717_CR15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41467-020-20746-4","volume":"12","author":"JR Fletcher","year":"2021","unstructured":"Fletcher JR, Pike CM, Parsons RJ, et al. Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota. Nat Commun. 2021;12:462. https:\/\/doi.org\/10.1038\/s41467-020-20746-4.","journal-title":"Nat Commun."},{"key":"1717_CR16","doi-asserted-by":"publisher","unstructured":"Brown KA, Langford B, Schwartz KL, Diong C, Garber G, Daneman N. Antibiotic prescribing choices and their comparative C. difficile infection risks: a longitudinal case-cohort study. Clin Infect Dis. 2021;72:836-44. https:\/\/doi.org\/10.1093\/cid\/ciaa124.","DOI":"10.1093\/cid\/ciaa124"},{"key":"1717_CR17","doi-asserted-by":"publisher","unstructured":"Webb BJ, Subramanian A, Lopansri B, et al. Antibiotic exposure and risk for hospital-associated Clostridioides difficile infection.\u00a0Antimicrob Agents Chemother. 2020;64:e02169-19.\u00a0https:\/\/doi.org\/10.1128\/aac.02169-19.","DOI":"10.1128\/aac.02169-19"},{"issue":"4","key":"1717_CR18","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/infdis\/jiaa773","volume":"224","author":"AC Miller","year":"2021","unstructured":"Miller AC, Sewell DK, Segre AM, Pemmaraju SV, Polgreen PM. Risk for Clostridioides difficile infection among hospitalized patients associated with multiple healthcare exposures prior to admission. J Infect Dis. 2021;224:684\u201394. https:\/\/doi.org\/10.1093\/infdis\/jiaa773.","journal-title":"J Infect Dis."},{"issue":"1","key":"1717_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s40001-023-01432-9","volume":"28","author":"MJ Fernandez-Cotarelo","year":"2023","unstructured":"Fernandez-Cotarelo MJ, Jackson-Akers JY, Nagy-Agren SE, Warren CA. Interaction of Clostridioides difficile infection with frailty and cognition in the elderly: a narrative review. Eur J Med Res. 2023;28:439. https:\/\/doi.org\/10.1186\/s40001-023-01432-9.","journal-title":"Eur J Med Res."},{"key":"1717_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ijid.2019.10.028","volume":"90","author":"T Avni","year":"2020","unstructured":"Avni T, Babitch T, Ben-Zvi H, et al. Clostridioides difficile infection in immunocompromised hospitalized patients is associated with a high recurrence rate. Int J Infect Dis. 2020;90:237\u201342. https:\/\/doi.org\/10.1016\/j.ijid.2019.10.028.","journal-title":"Int J Infect Dis."},{"issue":"10","key":"1717_CR21","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1177\/00031348221103644","volume":"88","author":"R Fazl Alizadeh","year":"2022","unstructured":"Fazl Alizadeh R, Li S, Sullivan B, et al. Surgical outcome in laparoscopic abdominal surgical operations with Clostridium difficile infection. Am Surg. 2022;88:2519\u201324. https:\/\/doi.org\/10.1177\/00031348221103644.","journal-title":"Am Surg."},{"key":"1717_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.01.008","author":"KM D'Silva","year":"2021","unstructured":"D\u2019Silva KM, Mehta R, Mitchell M, et al. Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Clin Microbiol Infect. 2021:S1198-743X(21)00035-5. https:\/\/doi.org\/10.1016\/j.cmi.2021.01.008.","journal-title":"Clin Microbiol Infect."},{"issue":"12","key":"1717_CR23","doi-asserted-by":"publisher","first-page":"e1084","DOI":"10.1093\/cid\/ciaa1857","volume":"72","author":"M Inghammar","year":"2021","unstructured":"Inghammar M, Svanstr\u00f6m H, Voldstedlund M, et al. Proton-pump inhibitor use and the risk of community-associated Clostridium difficile infection. Clin Infect Dis. 2021;72:e1084\u20139. https:\/\/doi.org\/10.1093\/cid\/ciaa1857.","journal-title":"Clin Infect Dis."},{"issue":"7","key":"1717_CR24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cix1085","volume":"66","author":"LC McDonald","year":"2018","unstructured":"McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66:e1\u201348. https:\/\/doi.org\/10.1093\/cid\/cix1085.","journal-title":"Clin Infect Dis."},{"issue":"6","key":"1717_CR25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciy381","volume":"67","author":"JM Miller","year":"2018","unstructured":"Miller JM, Binnicker MJ, Campbell S, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis. 2018;67:e1\u201394. https:\/\/doi.org\/10.1093\/cid\/ciy381.","journal-title":"Clin Infect Dis."},{"issue":"7","key":"1717_CR26","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/cid\/ciad334","volume":"77","author":"NA Turner","year":"2023","unstructured":"Turner NA, Krishnan J, Nelson A, et al. Assessing the impact of 2-step Clostridioides difficile testing at the healthcare facility level. Clin Infect Dis. 2023;77:1043\u20139. https:\/\/doi.org\/10.1093\/cid\/ciad334.","journal-title":"Clin Infect Dis."},{"issue":"Pt 11","key":"1717_CR27","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1099\/mic.0.042010-0","volume":"156","author":"GW Tannock","year":"2010","unstructured":"Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology (Reading). 2010;156 Pt 11:3354\u20139. https:\/\/doi.org\/10.1099\/mic.0.042010-0.","journal-title":"Microbiology (Reading)."},{"issue":"5","key":"1717_CR28","doi-asserted-by":"publisher","first-page":"e0211","DOI":"10.1128\/aac.02112-17","volume":"62","author":"NJ Ajami","year":"2018","unstructured":"Ajami NJ, Cope JL, Wong MC, Petrosino JF, Chesnel L. Impact of oral fidaxomicin administration on the intestinal microbiota and susceptibility to Clostridium difficile colonization in mice. Antimicrob Agents Chemother. 2018;62:e0211-17. https:\/\/doi.org\/10.1128\/aac.02112-17.","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"1717_CR29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","volume":"166","author":"AF Peery","year":"2024","unstructured":"Peery AF, Kelly CR, Kao D, et al. AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology. 2024;166:409\u201334. https:\/\/doi.org\/10.1053\/j.gastro.2024.01.008.","journal-title":"Gastroenterology."},{"issue":"5","key":"1717_CR30","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","volume":"73","author":"S Johnson","year":"2021","unstructured":"Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73:e1029\u201344. https:\/\/doi.org\/10.1093\/cid\/ciab549.","journal-title":"Clin Infect Dis."},{"issue":"6","key":"1717_CR31","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/dcr.0000000000002047","volume":"64","author":"V Poylin","year":"2021","unstructured":"Poylin V, Hawkins AT, Bhama AR, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection. Dis Colon Rectum. 2021;64:650\u201368. https:\/\/doi.org\/10.1097\/dcr.0000000000002047.","journal-title":"Dis Colon Rectum."},{"key":"1717_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2022.09.013","volume":"124","author":"M Krutova","year":"2022","unstructured":"Krutova M, Wilcox M, Kuijper E. Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view? Int J Infect Dis. 2022;124:118\u201323. https:\/\/doi.org\/10.1016\/j.ijid.2022.09.013.","journal-title":"Int J Infect Dis."},{"issue":"4","key":"1717_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa1602615","volume":"376","author":"MH Wilcox","year":"2017","unstructured":"Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376:305\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1602615.","journal-title":"N Engl J Med."},{"issue":"5","key":"1717_CR34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/cid\/ciy171","volume":"67","author":"DN Gerding","year":"2018","unstructured":"Gerding DN, Kelly CP, Rahav G, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile Infection in patients at increased risk for recurrence. Clin Infect Dis. 2018;67:649\u201356. https:\/\/doi.org\/10.1093\/cid\/ciy171.","journal-title":"Clin Infect Dis."},{"issue":"3","key":"1717_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/cix809","volume":"66","author":"VS Prabhu","year":"2018","unstructured":"Prabhu VS, Dubberke ER, Dorr MB, et al. Cost-effectiveness of bezlotoxumab compared with placebo for the prevention of recurrent Clostridium difficile infection. Clin Infect Dis. 2018;66:355\u201362. https:\/\/doi.org\/10.1093\/cid\/cix809.","journal-title":"Clin Infect Dis."},{"issue":"4","key":"1717_CR36","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/apt.13290","volume":"42","author":"A Fischer","year":"2015","unstructured":"Fischer A, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Alim Pharmacol Ther. 2015;42:470\u20136.","journal-title":"Alim Pharmacol Ther."},{"issue":"16","key":"1717_CR37","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1001\/jama.2023.4314","volume":"329","author":"T Louie","year":"2023","unstructured":"Louie T, Golan Y, Khanna S, et al. VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA. 2023;329:1356\u201366. https:\/\/doi.org\/10.1001\/jama.2023.4314.","journal-title":"Jama."},{"issue":"4","key":"1717_CR38","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1017\/ice.2014.80","volume":"36","author":"RU Varier","year":"2015","unstructured":"Varier RU, Biltaji E, Smith KJ, et al. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol. 2015;36:438\u201344. https:\/\/doi.org\/10.1017\/ice.2014.80.","journal-title":"Infect Control Hosp Epidemiol."},{"key":"1717_CR39","doi-asserted-by":"publisher","first-page":"175628482311742","DOI":"10.1177\/17562848231174277","volume":"16","author":"C Lee","year":"2023","unstructured":"Lee C, Louie T, Bancke L, et al. Safety of fecal microbiota, live-jslm (REBYOTA(\u2122)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials. Therap Adv Gastroenterol. 2023;16:17562848231174276. https:\/\/doi.org\/10.1177\/17562848231174277.","journal-title":"Therap Adv Gastroenterol."},{"key":"1717_CR40","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.09.030","author":"JR Allegretti","year":"2024","unstructured":"Allegretti JR, Kelly CR, Louie T, et al. Safety and tolerability of CP101, a full-spectrum, oral microbiome therapeutic for the prevention of recurrent Clostridioides difficile infection: a phase 2 randomized controlled trial. Gastroenterology. 2024:S0016-5085(24)05536-7. https:\/\/doi.org\/10.1053\/j.gastro.2024.09.030.","journal-title":"Gastroenterology."},{"issue":"3","key":"1717_CR41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","volume":"166","author":"AF Peery","year":"2024","unstructured":"Peery AF, Kelly CR, Kao D, et al. AGA clinical practice guideline on fecal microbiota\u2013based therapies for select gastrointestinal diseases. Gastroenterology. 2024;166:409\u201334. https:\/\/doi.org\/10.1053\/j.gastro.2024.01.008.","journal-title":"Gastroenterology."},{"issue":"3","key":"1717_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa2106516","volume":"386","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386:220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2106516.","journal-title":"N Engl J Med."},{"key":"1717_CR43","doi-asserted-by":"publisher","first-page":"842669","DOI":"10.3389\/fimmu.2022.842669","volume":"13","author":"Y Zhong","year":"2022","unstructured":"Zhong Y, Cao J, Ma Y, Zhang Y, Liu J, Wang H. Fecal microbiota transplantation donor and dietary fiber intervention collectively contribute to gut health in a mouse model. Front Immunol. 2022;13:842669. https:\/\/doi.org\/10.3389\/fimmu.2022.842669.","journal-title":"Front Immunol."},{"issue":"5","key":"1717_CR44","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3390\/nu13051487","volume":"13","author":"AK Clancy","year":"2021","unstructured":"Clancy AK, Lee C, Hamblin H, et al. Dietary intakes of recipients of faecal microbiota transplantation: an observational pilot study. Nutrients. 2021;13:1487. https:\/\/doi.org\/10.3390\/nu13051487.","journal-title":"Nutrients."},{"issue":"6","key":"1717_CR45","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1007\/s10620-018-5450-4","volume":"64","author":"JR Allegretti","year":"2019","unstructured":"Allegretti JR, Kao D, Phelps E, et al. Risk of Clostridium difficile infection with systemic antimicrobial therapy following successful fecal microbiota transplant: should we recommend anti-Clostridium difficile antibiotic prophylaxis? Dig Dis Sci. 2019;64:1668\u201371. https:\/\/doi.org\/10.1007\/s10620-018-5450-4.","journal-title":"Dig Dis Sci."},{"issue":"1","key":"1717_CR46","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/cid\/cix684","volume":"66","author":"JR Allegretti","year":"2018","unstructured":"Allegretti JR, Kao D, Sitko J, Fischer M, Kassam Z. Early antibiotic use after fecal microbiota transplantation increases risk of treatment failure. Clin Infect Dis. 2018;66:134\u20135. https:\/\/doi.org\/10.1093\/cid\/cix684.","journal-title":"Clin Infect Dis."},{"issue":"6","key":"1717_CR47","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.cell.2018.08.047","volume":"174","author":"J Suez","year":"2018","unstructured":"Suez J, Zmora N, Zilberman-Schapira G, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. 2018;174:1406\u201323.e16. https:\/\/doi.org\/10.1016\/j.cell.2018.08.047.","journal-title":"Cell."},{"issue":"1","key":"1717_CR48","doi-asserted-by":"publisher","first-page":"18349","DOI":"10.1038\/s41598-020-75162-x","volume":"10","author":"N Kazemian","year":"2020","unstructured":"Kazemian N, Ramezankhani M, Sehgal A, et al. The trans-kingdom battle between donor and recipient gut microbiome influences fecal microbiota transplantation outcome. Sci Rep. 2020;10:18349. https:\/\/doi.org\/10.1038\/s41598-020-75162-x.","journal-title":"Sci Rep."},{"key":"1717_CR49","doi-asserted-by":"publisher","unstructured":"Seekatz AM, Aas J, Gessert CE, et al. Recovery of the gut microbiome following fecal microbiota transplantation.\u00a0mBio. 2014;5:e00893\u201314.\u00a0https:\/\/doi.org\/10.1128\/mbio.00893-14.","DOI":"10.1128\/mbio.00893-14"},{"issue":"9","key":"1717_CR50","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jfma.2021.11.001","volume":"121","author":"P-C Lee","year":"2022","unstructured":"Lee P-C, Chang T-E, Wang Y-P, et al. Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in Clostridium difficile infection. J Form Med Assocn. 2022;121:1636\u201346.","journal-title":"J Form Med Assocn."},{"issue":"1","key":"1717_CR51","doi-asserted-by":"publisher","first-page":"2393766","DOI":"10.1080\/19490976.2024.2393766","volume":"16","author":"AS McMillan","year":"2024","unstructured":"McMillan AS, Theriot CM. Bile acids impact the microbiota, host, and C. difficile dynamics providing insight into mechanisms of efficacy of FMTs and microbiota-focused therapeutics. Gut Microbes. 2024;16:2393766. https:\/\/doi.org\/10.1080\/19490976.2024.2393766.","journal-title":"Gut Microbes."},{"key":"1717_CR52","doi-asserted-by":"publisher","unstructured":"Chen Q, Wu C, Xu J, et al. Donor-recipient intermicrobial interactions impact transfer of subspecies and fecal microbiota transplantation outcome. Cell Host Microbe. 2024;32:349-65.e4. https:\/\/doi.org\/10.1016\/j.chom.2024.01.013.","DOI":"10.1016\/j.chom.2024.01.013"},{"issue":"5","key":"1717_CR53","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.chom.2023.03.020","volume":"31","author":"S Porcari","year":"2023","unstructured":"Porcari S, Benech N, Valles-Colomer M, et al. Key determinants of success in fecal microbiota transplantation: From microbiome to clinic. Cell Host Microbe. 2023;31:712\u201333. https:\/\/doi.org\/10.1016\/j.chom.2023.03.020.","journal-title":"Cell Host Microbe."},{"issue":"12","key":"1717_CR54","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/cid\/ciw185","volume":"62","author":"B Millan","year":"2016","unstructured":"Millan B, Park H, Hotte N, et al. Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin Infect Dis. 2016;62:1479\u201386. https:\/\/doi.org\/10.1093\/cid\/ciw185.","journal-title":"Clin Infect Dis."},{"issue":"10","key":"1717_CR55","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1093\/cid\/cix618","volume":"65","author":"R Tariq","year":"2017","unstructured":"Tariq R, Pardi DS, Tosh PK, Walker RC, Razonable RR, Khanna S. Fecal microbiota transplantation for recurrent Clostridium difficile infection reduces recurrent urinary tract infection frequency. Clin Infect Dis. 2017;65:1745\u20137. https:\/\/doi.org\/10.1093\/cid\/cix618.","journal-title":"Clin Infect Dis."},{"issue":"1","key":"1717_CR56","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.chest.2017.09.002","volume":"153","author":"BJ Kelly","year":"2018","unstructured":"Kelly BJ, Tebas P. Clinical practice and infrastructure review of fecal microbiota transplantation for Clostridium difficile infection. Chest. 2018;153:266\u201377. https:\/\/doi.org\/10.1016\/j.chest.2017.09.002.","journal-title":"Chest."},{"issue":"4","key":"1717_CR57","doi-asserted-by":"publisher","first-page":"647","DOI":"10.14309\/ajg.0000000000001075","volume":"116","author":"S Gupta","year":"2021","unstructured":"Gupta S, Mullish BH, Allegretti JR. Fecal microbiota transplantation: the evolving risk landscape. Am J Gastroenterol. 2021;116:647\u201356. https:\/\/doi.org\/10.14309\/ajg.0000000000001075.","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"1717_CR58","doi-asserted-by":"publisher","first-page":"2052698","DOI":"10.1080\/19490976.2022.2052698","volume":"14","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Saint Fleur A, Feng H. The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota. Gut Microbes. 2022;14:2052698. https:\/\/doi.org\/10.1080\/19490976.2022.2052698.","journal-title":"Gut Microbes."},{"issue":"7","key":"1717_CR59","doi-asserted-by":"publisher","first-page":"e1613","DOI":"10.1093\/cid\/ciaa1430","volume":"73","author":"S Khanna","year":"2021","unstructured":"Khanna S, Pardi DS, Jones C, Shannon WD, Gonzalez C, Blount K. RBX7455, a non-frozen, orally administered investigational live biotherapeutic, is safe, effective, and shifts patients\u2019 microbiomes in a phase 1 study for recurrent Clostridioides difficile infections. Clin Infect Dis. 2021;73:e1613\u201320. https:\/\/doi.org\/10.1093\/cid\/ciaa1430.","journal-title":"Clin Infect Dis."},{"key":"1717_CR60","unstructured":"Inc. FP. REBYOTA[Package insert] 2022. Accessed 01 August 2024."},{"issue":"2","key":"1717_CR61","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40121-022-00744-3","volume":"12","author":"ER Dubberke","year":"2023","unstructured":"Dubberke ER, Orenstein R, Khanna S, Guthmueller B, Lee C. Final results from a phase 2b randomized, placebo-controlled clinical trial of RBX2660: a microbiota-based drug for the prevention of recurrent Clostridioides difficile infection. Infect Dis Ther. 2023;12:703\u20139. https:\/\/doi.org\/10.1007\/s40121-022-00744-3.","journal-title":"Infect Dis Ther."},{"issue":"1","key":"1717_CR62","doi-asserted-by":"publisher","first-page":"ofac703","DOI":"10.1093\/ofid\/ofac703","volume":"10","author":"G Tillotson","year":"2023","unstructured":"Tillotson G, Archbald-Pannone L, Johnson S, et al. Microbiota-based live biotherapeutic RBX2660 for the reduction of recurrent Clostridioides difficile Infection in older adults with underlying comorbidities. Open Forum Infect Dis. 2023;10:ofac703. https:\/\/doi.org\/10.1093\/ofid\/ofac703.","journal-title":"Open Forum Infect Dis."},{"key":"1717_CR63","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae418","author":"KF Blount","year":"2024","unstructured":"Blount KF, Papazyan R, Ferdyan N, et al. Microbiome and metabolome restoration after administration of fecal microbiota, live-jslm (REBYOTA\u00ae) for preventing recurrent Clostridioides difficile infection. J Infect Dis. 2024:jiae418. https:\/\/doi.org\/10.1093\/infdis\/jiae418.","journal-title":"J Infect Dis."},{"issue":"1","key":"1717_CR64","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12879-022-07256-y","volume":"22","author":"R Orenstein","year":"2022","unstructured":"Orenstein R, Dubberke ER, Khanna S, et al. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infect Dis. 2022;22:245. https:\/\/doi.org\/10.1186\/s12879-022-07256-y.","journal-title":"BMC Infect Dis."},{"issue":"4","key":"1717_CR65","doi-asserted-by":"publisher","first-page":"ofz095","DOI":"10.1093\/ofid\/ofz095","volume":"6","author":"KF Blount","year":"2019","unstructured":"Blount KF, Shannon WD, Deych E, Jones C. Restoration of bacterial microbiome composition and diversity among treatment responders in a phase 2 trial of RBX2660: an investigational microbiome restoration therapeutic. Open Forum Infect Dis. 2019;6:ofz095. https:\/\/doi.org\/10.1093\/ofid\/ofz095.","journal-title":"Open Forum Infect Dis."},{"issue":"3","key":"1717_CR66","doi-asserted-by":"publisher","first-page":"ofad113","DOI":"10.1093\/ofid\/ofad113","volume":"10","author":"KW Garey","year":"2023","unstructured":"Garey KW, Feuerstadt P, Dubberke ER, Guo A, Tillotson GS. Effect of fecal microbial transplantation on Clostridioides difficile infection: dysbiosis, metabolites and health related quality of life. Open Forum Infect Dis. 2023;10:ofad113. https:\/\/doi.org\/10.1093\/ofid\/ofad113.","journal-title":"Open Forum Infect Dis."},{"key":"1717_CR67","doi-asserted-by":"crossref","unstructured":"Khanna S, Dubberke ER, Knapple WL, et al. S132\u2003An interim analysis of a phase 3, open-label study indicates efficacy and safety of RBX2660 in patients with recurrent Clostridioides difficile infection.\u00a0Am J Gastroenterol. 2022;117(10S).","DOI":"10.14309\/01.ajg.0000857168.31201.9f"},{"key":"1717_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae437","author":"P Feuerstadt","year":"2024","unstructured":"Feuerstadt P, Chopra T, Knapple W, et al. PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent Clostridioides difficile infection. Clin Infect Dis. 2024:ciae437. https:\/\/doi.org\/10.1093\/cid\/ciae437.","journal-title":"Clin Infect Dis."},{"issue":"6","key":"1717_CR69","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s12325-023-02505-1","volume":"40","author":"T Lodise","year":"2023","unstructured":"Lodise T, Guo A, Yang M, et al. Cost-effectiveness analysis of REBYOTA\u2122 (fecal microbiota, live-jslm [FMBL]) versus standard of care for the prevention of recurrent Clostridioides difficile infection in the USA. Adv Ther. 2023;40:2784\u2013800. https:\/\/doi.org\/10.1007\/s12325-023-02505-1.","journal-title":"Adv Ther."},{"issue":"3","key":"1717_CR70","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-024-02006-7","volume":"84","author":"HA Blair","year":"2024","unstructured":"Blair HA. SER-109 (VOWST\u2122):\u00a0a review in the prevention of recurrent Clostridioides difficile infection. Drugs. 2024;84:329\u201336. https:\/\/doi.org\/10.1007\/s40265-024-02006-7.","journal-title":"Drugs."},{"issue":"12","key":"1717_CR71","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1093\/cid\/ciaa387","volume":"72","author":"BH McGovern","year":"2021","unstructured":"McGovern BH, Ford CB, Henn MR, et al. SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: lessons learned from a phase 2 trial. Clin Infect Dis. 2021;72:2132\u201340. https:\/\/doi.org\/10.1093\/cid\/ciaa387.","journal-title":"Clin Infect Dis."},{"issue":"2","key":"1717_CR72","doi-asserted-by":"publisher","first-page":"e2255758","DOI":"10.1001\/jamanetworkopen.2022.55758","volume":"6","author":"MD Sims","year":"2023","unstructured":"Sims MD, Khanna S, Feuerstadt P, et al. Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single-arm trial. JAMA Netw Open. 2023;6:e2255758. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.55758.","journal-title":"JAMA Netw Open."},{"issue":"1","key":"1717_CR73","doi-asserted-by":"publisher","first-page":"e2253570","DOI":"10.1001\/jamanetworkopen.2022.53570","volume":"6","author":"KW Garey","year":"2023","unstructured":"Garey KW, Jo J, Gonzales-Luna AJ, et al. Assessment of quality of life among patients with recurrent Clostridioides difficile infection treated with investigational oral microbiome therapeutic SER-109: secondary analysis of a randomized clinical trial. JAMA Netw Open. 2023;6:e2253570. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.53570.","journal-title":"JAMA Netw Open."},{"issue":"11","key":"1717_CR74","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/cid\/ciad448","volume":"77","author":"CS Berenson","year":"2023","unstructured":"Berenson CS, Lashner B, Korman LY, et al. Prevalence of comorbid factors in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a randomized trial of an oral microbiota-based therapeutic. Clin Infect Dis. 2023;77:1504\u201310. https:\/\/doi.org\/10.1093\/cid\/ciad448.","journal-title":"Clin Infect Dis."},{"issue":"2","key":"1717_CR75","doi-asserted-by":"publisher","first-page":"e2255758-e","DOI":"10.1001\/jamanetworkopen.2022.55758","volume":"6","author":"MD Sims","year":"2023","unstructured":"Sims MD, Khanna S, Feuerstadt P, et al. Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single-arm trial. JAMA Network Open. 2023;6:e2255758-e.","journal-title":"JAMA Network Open."},{"issue":"6","key":"1717_CR76","doi-asserted-by":"publisher","first-page":"S-141","DOI":"10.1016\/S0016-5085(23)01301-X","volume":"164","author":"ES Huang","year":"2023","unstructured":"Huang ES, Lashner B, Sims M, et al. 694 Durability of the clinical response to SER-109, an investigational oral microbiome therapeutic, in a phase 3 open-label trial (ECOSPOR IV) in patients with recurrent Clostridioides difficile infection. Gastroenterology. 2023;164:S-141.","journal-title":"Gastroenterology."},{"key":"1717_CR77","doi-asserted-by":"crossref","unstructured":"Lashner B, von Moltke L, De A, Pardi DS. S77 Safety and efficacy of fecal microbiota spores, live-brpk (formerly SER-109) in older patients with recurrent Clostridioides difficile infection: findings from an integrated analysis of phase 3 trials.\u00a0Am J Gastroenterol. 2023;118(12S):S21.","DOI":"10.14309\/01.ajg.0000996052.73742.a6"},{"issue":"3","key":"1717_CR78","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/antibiotics12030435","volume":"12","author":"P Etifa","year":"2023","unstructured":"Etifa P, Rodr\u00edguez C, Harmanus C, et al. Non-toxigenic Clostridioides difficile strain E4 (NTCD-E4) prevents establishment of primary C. difficile infection by epidemic PCR ribotype 027 in an in vitro human gut model. Antibiotics. 2023;12:435.","journal-title":"Antibiotics."},{"key":"1717_CR79","doi-asserted-by":"crossref","unstructured":"Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C difficile infection: a randomized clinical trial. JAMA. 2015;313:1719\u201327.","DOI":"10.1001\/jama.2015.3725"},{"issue":"2","key":"1717_CR80","doi-asserted-by":"publisher","first-page":"e0051723","DOI":"10.1128\/spectrum.00517-23","volume":"11","author":"SP Sambol","year":"2023","unstructured":"Sambol SP, Skinner AM, Serna-Perez F, Owen B, Gerding DN, Johnson S. Effective colonization by nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) spores following treatment with either fidaxomicin or vancomycin. Microbiol Spectr. 2023;11:e0051723. https:\/\/doi.org\/10.1128\/spectrum.00517-23.","journal-title":"Microbiol Spectr."},{"issue":"10","key":"1717_CR81","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1128\/aac.00913-12","volume":"56","author":"SA Villano","year":"2012","unstructured":"Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother. 2012;56:5224\u20139. https:\/\/doi.org\/10.1128\/aac.00913-12.","journal-title":"Antimicrob Agents Chemother."},{"key":"1717_CR82","doi-asserted-by":"crossref","unstructured":"Nale JY, Spencer J, Hargreaves KR, et al. Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrobial Agents Chemother. 2016;60:968\u201381.","DOI":"10.1128\/AAC.01774-15"},{"key":"1717_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.891790","volume":"13","author":"J Venhorst","year":"2022","unstructured":"Venhorst J, van der Vossen J, Agamennone V. Battling enteropathogenic Clostridia: phage therapy for Clostridioides difficile and Clostridium perfringens. Front Microbiol. 2022;13: 891790. https:\/\/doi.org\/10.3389\/fmicb.2022.891790.","journal-title":"Front Microbiol."},{"key":"1717_CR84","doi-asserted-by":"publisher","first-page":"1259427","DOI":"10.3389\/fmed.2023.1259427","volume":"10","author":"AA Umansky","year":"2023","unstructured":"Umansky AA, Fortier LC. The long and sinuous road to phage-based therapy of Clostridioides difficile infections. Front Med (Lausanne). 2023;10:1259427. https:\/\/doi.org\/10.3389\/fmed.2023.1259427.","journal-title":"Front Med (Lausanne)."}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-024-01717-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-024-01717-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-024-01717-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T04:20:23Z","timestamp":1737001223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-024-01717-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":84,"alternative-id":["1717"],"URL":"https:\/\/doi.org\/10.1007\/s12664-024-01717-9","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PB: none. SK: research grants from Rebiotix, Inc. (A Ferring company), Seres, Finch, Vedanta and Pfizer; consulting fees from Takeda, Rise and ProbioTech Inc, outside of the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable (no human participants involved).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members,\u00a0the Indian Society of Gastroenterology or the printer\/publishers are responsible for the results\/findings and content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}